The signal before the trial
Evidence that Intangia's triage layer anticipates clinical entry: a temporally controlled replay with scoring cutoffs from 2010 to 2023 across 100 disease and target areas, using only records dated at or before each historical cutoff. A 1-in-4 top-20 shortlist hit rate, named PD-1 and CTLA-4 alerts, and breadth scores.
Open report → ADC / TCE / CAR-T · CRC & LungColorectal & lung surface targets, three-modality
Cell-surface targets in colorectal cancer, NSCLC and SCLC, scored for antibody-drug-conjugate, T-cell-engager and CAR-T developability. A per-target modality-fit heatmap shows which format each target favours, plus mature and novel lists and the full developable set.
Open report → ADC / TCE · CRC & LungColorectal & lung surface targets
Cell-surface targets in colorectal cancer, NSCLC and SCLC, prioritised for antibody-drug-conjugate and T-cell-engager developability. Mature and novel lists plus the full developable set.
Open report → Indications · Unmet NeedDisease unmet-need landscape
1,000 indications scored and ranked by therapeutic unmet need — treatment landscape, prevalence and pipeline depth — then enriched with genetic targets, modalities and mechanisms. Full ranked table, top-40 detail, and a burden × therapy-gap map.
Open report →